GPCR News

Post: Blog2_Post

AELIS PHARMA launches their IPO for €25 million

February 2022

"We are proud to announce the success of our IPO!

Thank you to our shareholders, both historical and new, for their trust.

The €25 million fundraising gives us the means to achieve our ambitions: to become a leading player in the field of brain diseases!

November 2022 "Neuropeptides produce robust effects on behavior across species, and recent research has benefited from advances in...

November 2022 "Some G protein-coupled receptor (GPCR) ligands act as "biased agonists" that preferentially activate specific signaling...

November 2022 Deciphering the signaling mechanisms of β-arrestin1 and β-arrestin2 in regulation of cancer cell cycle and metastasis...